Background Cytomegalovirus (CMV) is the most common opportunistic infection after solid-
organ transplantation, increasing morbidity and mortality. Three months of oral …

Background Cytomegalovirus (CMV) can cause severe infections in transplanted patients.
To prevent CMV infection, most liver centers use prophylaxis for CMV-seronegative …

Background Cytomegalovirus (CMV) is a common opportunistic infection in patients after
liver transplant (LT). Guidelines recommend 900 mg daily of valganciclovir; however …

Cytomegalovirus (CMV) infection frequently occurs after solid organ transplantation and is
associated with an increased morbidity and mortality. Fortunately, the development of …

Cytomegalovirus (CMV) infection is the most common viral infection in liver transplant
recipients, affecting post-transplant patients and graft survival. Recent advances in …

CMV disease rate of 1% among all patients and a rate of 10% among those at risk for
primary CMV infection (seronegative recipients of seropositive allografts)[24]. However …

Objectives: Cytomegalovirus (CMV) infection is responsible for significant morbidity and
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …

Background The role of secondary cytomegalovirus (CMV) prophylaxis, defined as the
continuation of valganciclovir to prevent relapse after the successful treatment of CMV …

Cytomegalovirus infection (CMV) in solid organ transplant recipients is a major clinical
problem. The aim of this study was to evaluate the incidence of CMV infection and its …

Human cytomegalovirus (CMV) remains a major cause of mortality and morbidity in human
liver transplant recipients. Anti-CMV therapeutics can be used to prevent or treat CMV in …